EGFR and neoplasm: reported that normalization of tumor vasculature upon being treated with EGFR inhibitors at a moderate dose could not only improve the tumor perfusion of oxygen and nanoscale therapeutic agents, but also alter the immunosuppressive TME by relieving the tumor hypoxia [170].